Table 1. CART19 trials in adult patients... | American Society of Hematology

Table 1.

CART19 trials in adult patients with r/r acute lymphoblastic leukemia

Reference	CART domain	N treated	Median age	Prior Blina, %	Prior HSCT, %	CR/Cri, %	CRS	ICANS
Park, NEJM, 2018¹⁰	CD28	53	44 (23-64)	25	36	83	85% Total 26% Severe 1 Gr 5	42% Gr 3 to 4
Hay, Blood, 2019⁹	41BB	53	39 (20-76)	20	43	85	75% Total 19% Gr 3 to 4	23% Total
Frey, JCO, 2020⁸	41BB	35	34 (21-70)	31	37	69	94% Total 9% Gr 4 to 5	40% Total 6% Gr 3
Roddie, JCO, 2021¹⁴	41BB	20	41.4 (18-62)	25	65	85	55% Total 0% ≥ Gr 3	15% Gr 3
Shah, Lancet, 2021¹⁶	CD28	55	40 (28-52 IQR) 15% > 65	45	42	71	89% Total ≥ Gr 3 = 25%	60% Total 23% Gr 3 1 Gr 5

Reference	CART domain	N treated	Median age	Prior Blina, %	Prior HSCT, %	CR/Cri, %	CRS	ICANS
Park, NEJM, 2018¹⁰	CD28	53	44 (23-64)	25	36	83	85% Total 26% Severe 1 Gr 5	42% Gr 3 to 4
Hay, Blood, 2019⁹	41BB	53	39 (20-76)	20	43	85	75% Total 19% Gr 3 to 4	23% Total
Frey, JCO, 2020⁸	41BB	35	34 (21-70)	31	37	69	94% Total 9% Gr 4 to 5	40% Total 6% Gr 3
Roddie, JCO, 2021¹⁴	41BB	20	41.4 (18-62)	25	65	85	55% Total 0% ≥ Gr 3	15% Gr 3
Shah, Lancet, 2021¹⁶	CD28	55	40 (28-52 IQR) 15% > 65	45	42	71	89% Total ≥ Gr 3 = 25%	60% Total 23% Gr 3 1 Gr 5

Blina, blinatumomab; Gr, grade; N, number.